Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients

The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade(R) or Inflectra(R) to Flixabi(R) in patients with severe refractory sarcoidosis. This single center retrospective cohort study was performed at St Antonius Hospital Nieuwegein, The Netherlands. All patients diagnosed with severe refractory sarcoidosis receiving Remicade(R) or Inflectra(R) switched to Flixabi(R). The primary outcome was infliximab discontinuation within 6 months of switching. Secondary endpoints included adverse events and loss of clinical, functional, or inflammatory response. Out of 86 patients who switched to Flixabi(R), 79 patients had complete data. None of the 79 patients discontinued infliximab during the first 6 months after switching. Five patients reported an adverse event related to Flixabi(R) treatment. We found no change from baseline in FVC, FEV1, DLCOc, 6MWT, and infliximab trough levels 26 weeks after switching. An improvement in physical functioning of 7.3 +/- 13.4 points (p = 0.002) with RAND/SF36 and in biomarker sIL-2R (-475.58 +/- 1452.39; p = 0.005) was observed. Switching from originator infliximab Remicade(R) or biosimilar infliximab Inflectra(R) to biosimilar infliximab Flixabi(R) did not result in treatment discontinuation or loss of clinical/functional/inflammatory remission.

Automated summary

Switching from originator infliximab Remicade(R) or biosimilar infliximab Inflectra(R) to biosimilar infliximab Flixabi(R) did not result in treatment discontinuation or loss of clinical/functional/inflammatory remission among patients with severe refractory sarcoidosis.